Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Genetically modified mammal" patented technology

Genetically modified mammals are mammals that have been genetically engineered. They are an important category of genetically modified organisms. The majority of research involving genetically modified mammals involves mice with attempts to produce knockout animals in other mammalian species limited by the inability to derive and stably culture embryonic stem cells.

Genetically modified mammalian cell having susceptibility to human sapovirus infection, genetically modified mammal having said cell, and method for producing human sapovirus, method for imparting infection susceptibility, and screening method using said cell or mammal

The present invention addresses the problem of providing: a genetically modified cultured cell or a genetically modified animal each allowing a human sapovirus to proliferate regardless of host characteristics as barriers to proliferation in mammalian cells; and an application of the cell or animal to a screening method. The present inventors have solved the problem by finding that a genetically modified cultured mammalian cell having a human CD36-encoding gene incorporated therein and a mammal having such a cell as a self-cell show acquired susceptibility to human sapovirus infection, and providing, for example, a screening method for a drug relevant to a human sapovirus on the basis of the finding.
Owner:THE KITASATO INSTITUTE

Transgenic mammals and methods of use thereof

PendingJP2026026076ANucleic acid vectorBlood/immune system cellsTherapeutic antibodyImmunoglobulin light chain
To provide transgenic mammals expressing bovine-based immunoglobulins, including transgenic rodents expressing bovine-based immunoglobulins for the development of bovine therapeutic antibodies.SOLUTION: A transgenic rodent or rodent cell is provided comprising an engineered partially bovine immunoglobulin light chain locus comprising bovine immunoglobulin λ light chain variable region gene segments, wherein the engineered immunoglobulin locus is capable of expressing immunoglobulins comprising bovine variable domains, and wherein the transgenic rodent produces or is likely to produce more immunoglobulins comprising λ light chains than immunoglobulins comprising κ light chains.SELECTED DRAWING: Figure 13
Owner:TRIANNI INC

VHH-containing heavy chain antibody and production thereof

The present invention contemplates isolated polynucleotide for the production of a VHH-containing heavy chain antibody in a mammal and vectors comprising said isolated polynucleotide. Moreover, the invention relates to a transgenic mammal comprising the vector for the production of a VHH-containing heavy chain antibody. Further, the invention relates to VHH-containing heavy chain antibodies as well as methods for the production and cloning of VHH-containing heavy chain antibodies.
Owner:UNIVERSITAETSKLINIKUM HAMBURG EPPENDORF

Single chain VH and heavy chain antibodies

The present invention provides cells, transgenic animals, including transgenic mammals and particularly rodents comprising engineered immunoglobulin (Ig) alleles. Such engineered alleles, wherein an Ig light chain CL exon [Cκ or Cλ (Cλ1, Cλ2 or Cλ3)] is incorporated into the Ig heavy chain locus, are capable of producing heavy chain-only antibodies as a single chain VH antibody (scVHAb) or heavy chain antibody (HCAb) comprising two extended scVHAbs. The scVHAb comprises an antigen-binding part consisting of a VH domain and the immunoglobulin constant domains CL, which is either Cκ or Cλ, and CH1, in the orderfrom N-terminus to C-terminus: VH-L1-CL-L2-CH1, wherein L1 and L2 are each, independently, peptidic linkers; and wherein CL is paired with CH1 through beta-sheet contact thereby obtaining a CL / CH1 dimer.
Owner:TRIANNI INC

Genetically modified mammalian cells susceptible to human sapovirus infection, genetically modified mammals possessing such cells, and methods for producing human sapovirus using these, methods for conferring infection susceptibility, and screening methods.

ActiveJP7911449B2TransgenesisSapovirus
The present invention addresses the problem of providing: a genetically modified cultured cell or a genetically modified animal each allowing a human sapovirus to proliferate regardless of host characteristics as barriers to proliferation in mammalian cells; and an application of the cell or animal to a screening method. The present inventors have solved the problem by finding that a genetically modified cultured mammalian cell having a human CD36-encoding gene incorporated therein and a mammal having such a cell as a self-cell show acquired susceptibility to human sapovirus infection, and providing, for example, a screening method for a drug relevant to a human sapovirus on the basis of the finding.
Owner:THE KITASATO INSTITUTE